Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 9, 2003, Pages 1097-1107

  Orenstein, S R ^a   Shalaby, T M ^a   Devandry, S N ^a   Liacouras, C A ^b   Czinn, S J ^c   Dice, J E ^a   Simon, T J ^d   Ahrens, S P ^d   Stauffer, L A ^d  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; PLACEBO;

AGITATION; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HICCUP; HUMAN; INFANT; IRRITABILITY; MALE; MOOD DISORDER; MULTICENTER STUDY; NEUTROPENIA; OTITIS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; FAMOTIDINE; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; TREATMENT OUTCOME;

EID: 0037852105     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01559.x     Document Type: Article

References (21)

1. Orenstein S. Gastroesophageal reflux. In: Hyman P, Di Lorenzo C. eds. Pediatric Gastrointestinal Motility Disorders. New York: Academy Professional Information Services. 1994: 55-88.
2. Shalaby TM, Orenstein SR. Efficacy of telephone teaching of conservative therapy for infants with symptomatic gastroesophageal reflux referred by pediatricians to pediatric gastroenterologists. J Pediatr 2003; 142: 57-61.
3. Carroll A, Garrison M, Christakis D. A systematic review of nonpharmacological and nonsurgical therapies for gastroesophageal reflux in infants. Arch Pediatr Adolesc Med 2002; 156: 109-13.
4. Kelly D. Do H2 receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol Nutr 1994; 19(3): 270-6.
5. Lambert J, Mobassaleh M, Grand R. Efficacy of cimetidine for gastric acid suppression in pediatric patients. J Pediatr 1992; 120(3): 474-8.
6. Galmische JP, Brandstatter G, Evreux M, et al. Control of severe reflux oesophagitis with combined cisapride-cimetidine treatment: a double-blind controlled trial. In: Johnson AG, Lux G, eds. Progress in the Treatment of Gastrointestinal Motility Disorders. The Role of Cisapride. Amsterdam: Excerpta Medica, 1988: 74-5.
7. Lieberman D, Keeffe E. Treatment of severe reflux esophagitis with cimetidine and metoclopramide. Ann Intern Med 1986; 104(1): 21-6.
8. Cucchiara S, Gobio-Casali L, Balli F. et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Pediatr Gastroenterol Nutr 1989; 8(2): 150-6.
9. Alliet P, Raes M, Bruneel E, Gillis P. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998; 132(2): 352-4.
10. Sabesin S, Berlin R, Humphries T, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations: results of a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med 1991; 151: 2394-400.
11. Marrero J, de Caestecker J, Maxwell J. Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut 1994; 35: 447-50.
12. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21(3): 178-94.
13. Yeh KC, Chremos AN, Lin JH, et al. Single-dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos 1987; 8: 549-60.
14. James LP, Marshall JD, Heulitt MJ, Wells TG, Letzig L, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in children. J Clin Pharmacol 1996; 36: 48-54.
15. Treem W, Davis P, Hyams J. Suppression of gastric acid secretion by intravenous administration of famotidine in children. J Pediatr 1991; 118(5): 812-6.
16. Kraus G, Krishna DR, Chmelarsch D, Schmid H, Klotz U. Famotidine, Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. Clin Pharmacokinet 1990; 18: 77-81.
17. Nagita A, Manago M, Aoki S, Mino M, Suzuli K, Ashida K. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 1994; 16(5): 444-9.
18. James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 1998; 38: 1089-95.
19. U.S. Package Circular: PEPCID® (Tablets for Oral Suspension and Orally Disintegrating Tablets). Whitehouse, NJ: November 1998.
20. Orenstein S, Shalaby T, Cohn J. Reflux symptoms in 100 normal infants. Diagnostic validity of the Infant Gastroesophageal Reflux Questionnaire. Clin Pediatr 1996; 35(12): 607-14.
21. Spilker B. Guide to Clinical Studies and Developing Protocols. New York: Raven Press, 1984: 1-302.